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INTRODUCTION 
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Staphylococcus aureus is a gram-positive coccus frequently found in the 
nose, respiratory tract, and on the skin. Although Staphylococcus aureus is not 
always pathogenic, it is a common cause of skin infections such as abscesses, 
respiratory infections such as sinusitis, and food poisoning. Infections are 
produced by virulent strains that induce potent protein toxins, and expressing 
cell-surface proteins that bind and inactivate antibodies. Staphylococcus aureus 
can cause a range of illnesses, from minor skin infections, such as pimples, 
impetigo, boils, cellulitis, folliculitis, carbuncles, scalded skin syndrome, and 
abscesses, to life-threatening diseases of respiratory tract, CNS and bones toxic 
shock syndrome, bacteremia, and sepsis. It is still one of the five most common 
causes of hospital-acquired infections and is often the cause of postsurgical 
wound infections.1 
Staphylococcus aureus is the single most important cause of 
bloodstream infections in Intensive Care Unit (ICU) and staphylococci are the 
dominant species in positive blood cultures.  Staphylococcus aureus is perhaps 
the pathogen of greatest concern because of its intrinsic virulence, its ability to 
cause a diverse array of life threatening infections, and its capacity to adapt to 
different environmental conditions. The mortality of Staphylococcus aureus 
bacteremia remains approximately 20–40% despite the availability of effective 
antimicrobials.2 Staphylococcus aureus is now the leading overall cause of 
nosocomial infections and as more patients are treated outside the hospital 
setting, is an increasing concern in community. 
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Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium 
responsible for several difficult-to-treat infections in humans. MRSA is any 
strain of Staphylococcus aureus that has developed, through horizontal gene 
transfer and natural selection, multi- resistance to beta -lactam antibiotics and 
Quinolones. The emergence of antibiotic-resistant strains of Staphylococcus 
aureus such as Methicillin-resistant Staphylococcus aureus (MRSA) is a 
worldwide problem in clinical medicine. 
 Nosocomial infections are produced mostly by MRSA in patients with 
poor immune systems, open wounds and devices which are invasive. This 
situation is common in hospitals, prisons, and nursing homes than the general 
public. The healthcare-associated MRSA is designated as HA-MRSA and 
community-associated MRSA is defined as CA-MRSA and LA-MRSA 
(livestock-associated) reflect this distinction. Methicillin - resistant 
Staphylococcus aureus (MRSA) is a persistent problem in community and 
health care settings. 
Quinolone resistance among Staphylococcus aureus emerged quickly, 
more prominently among the methicillin-resistant strains. Fluoroquinolones can 
not be used as antistaphylococcal agents effectively and its efficacy was 
dramatically reduced. The rates of quinolone resistance between MSSA and 
MRSA differ significantly and reason for this is uncertain. One contributing 
factor is likely antibiotic selective pressure, especially in the hospital setting, 
resulting in the selection and spread of the more antibiotic-resistant MRSA 
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strains.3 These resident, resistant strains then become the reservoir for future 
infections.   
   The alarming rise in antibiotic resistance among pathogenic bacteria is 
a persistent issue in antibiotic therapy in health care and community settings. 
The fluoroquinolone class of antimicrobial agents has broad acceptance in 
hospitalized and community patients, and usage appears to be increasing. 
Although some members of the class (temafloxacin, grepafloxacin, gatifloxacin 
and trovafloxacin) have been withdrawn or restricted because of adverse 
events. New members of fluoroquinolones continue to be developed and 
approved for treating patients with respiratory tract infections, the single most 
common group of infections. Fluoroquinolones can be used once or twice a 
day, oral dosing and this easy way increases its use. As we approach the 
halfway point of the second decade of fluoroquinolone use, resistance has 
already emerged in some species of bacteria and some clinical settings.4 
 This study has been undertaken to examine the mechanisms of 
fluoroquinolone resistance and discuss epidemiologic factors that may have 
contributed to the prevalence of antibiotic resistance in clinical settings. 
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BRIEF HISTORY: 
The discovery of Staphylococcus aureus was initiated by the 
microscopic observation of the pus from infected tissue by Alexander Ogston 
(1844-1929). In 1882, he named the clustered micrococci "Staphylococci," 
from the Greek staphyle, meaning bunch of grapes. With several experiments 
on guinea pigs and mice, he also provided evidence that this bacterium caused 
the abscesses seen in infected tissues and septicemia5. However, the presence 
of Staphylococcus aureus was officially described and named after it was 
isolated in 1884 by Anton Rosenbach, who grew the two strains, 
Staphylococcus aureus (“golden staph,” for the golden colonies) and 
Staphylococcus albus (white colonies). 
The treatment against infections  by this bacterium remained very poor, 
leading to a high rate of mortality worldwide in hospitals until the introduction 
of penicillin in the early 1940s6. This antibiotic became an incredibly strong 
weapon to cure several staphylococcus infections; however, by the late 1940s 
penicillin-resistant staphylococcus outbreaks began to occur.  When penicillin 
was no longer efficient to control staphylococcus infections, the antibiotic 
methicillin was introduced but as this was used and within the short time until 
1961, it became less efficient because of repeated cases of resistance. The 
bacteria evolving resistance to methicillin was first detected in hospital and 
these were called methicillin-resistant Staphylococcus aureus or known as 
MRSA. Afterwards MRSA strains were known to be not only resistant to 
methicillin but also a range of penicillin-like antibiotics (beta-lactams) such as 
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amoxicillin, oxacillin methicillin, cephalosporins and other agents such as 
erythromycin, aminoglycosides, sulfamethoxazol-trimethoprim 7. 
 The glycopeptide, vancomycin became the last line of defence against 
Staphylococcus aureus infections. In 2002 there was the first report of MRSA 
strains with reduced susceptibility to vancomycin, in Japan. Following this 
finding, vancomycin resistance in enterococci (VRE) was believed to have 
transferred the genes conferring vancomycin resistance to Staphylococcus 
aureus.8 The vancomycin resistant Staphylococcus aureus   strain (VRSA) was 
first isolated in US (Centers for Disease and Prevention 2002) and then several 
countries including France, South Africa, Brazil and Korea also reported the 
presence of VRSA. This issue reflects the global dissemination of these 
antibiotic resistant bacteria, referred to as “superbugs”. As a result, the 
requirement for new alternative drugs is urgent; even now for linezolid and 
teicoplanin  that are currently used for the last line of treatment 9 there are 
resistant Staphylococcus aureus  isolates reported. 
 
MORPHOLOGICAL AND BIOCHEMICAL FEATURES: 
Staphylococcus aureus is a Gram-positive cocci facultative anaerobe 
and is a member of the Staphylococcaceae family. More than 30 
staphylococcal species are pathogenic, and Staphylococcus aureus is the most 
virulent among them. Its cell wall is from 0.5 to 1.5 µm in size and is naturally 
arranged in grape-like clusters or groups. It is also a non-motile and non-
sporing bacterium. Some strains of Staphylococcus aureus are capsulated and 
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are more virulent than non-capsulated form because the capsular 
polysaccharide can facilitate the adherence of the bacterium to the host cells 
and also functions by inhibiting the phagocytosis 10. 
Staphylococcus aureus forms smooth, medium to large colonies which 
are often yellow. On blood agar medium, the colonies are bigger than those on 
nutrient agar and most strains are beta-haemolytic 11 and they produce golden 
yellow pigment on nutrient agar. 
 
Pigmentation: 
 Carotenoids produced by bacteria are known to act as antioxidants 
which clear the local reactive oxygen species as shown in several in vitro and 
in vivo experiments. There are a group of orange and yellow pigments which 
cause the yellowish colonies for Staphylococcus aureus. These pigments are 
produced from C30 triterpenoid biosynthetic pathway and staphyloxanthin is 
the end product12 
In addition, Staphylococcus aureus can grow on MacConkey agar, 
mannitol salt agar. Staphylococcus aureus is capable of prolonged survival on 
environmental surfaces in varying conditions. It can grow on the wide range of 
temperature (7 to 48oC) and pH (4 to 10) but the optimum temperature is 35 to 
37oC and optimum pH is 7 to 7.5. It also can grow in high salt concentrations 
up to 25%. The bacterial cells are destroyed by heat but the toxin produced by 
them is extremely heat resistant, it can withstand heat at 60oC in 30 minutes, 
resulting in the food poisoning and the disease toxic shock syndrome (TSS). 
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The biochemical properties of Staphylococcus aureus are characterized 
by the fermentation of several sugars such as glucose, sucrose, lactose, maltose 
and mannitol. Furthermore, it can hydrolyze urea, reduce nitrates to nitrites and 
liquefy gelatin and it produces DNases. It is positive to catalase, protein A but 
negative to oxidase, and this is one of the features that can be used to 
differentiate Staphylococci and Streptococci.  
 
Catalase:  
 Catalase is an enzyme used for the decomposition of hydrogen peroxide 
that is known as a common antimicrobial substance mediated by leukocyte 
bactericidal mechanisms or by the competitive interference with other species 
such as Streptococci (Streptococcus sanguinis) and Lactobacilli. Catalase can 
be produced by a number of bacteria but some studies have shown that it is an 
important virulence factor in these bacteria such as the catalase produced from 
Lactobacilli can inhibit the growth of Neisseria gonorrhoeae. In 
Staphylococcus aureus, catalase has been shown to contribute significantly to 
the survival in murine macrophages and competition with other pathogens such 
as S. pneumoniae both in vitro and in a murine model of nasal colonisation13. 
Coagulase positivity is another feature to differentiate between 
Staphylococcus aureus and coagulase negative Staphylococcus such as S. 
epidermidis and S. capitis. 
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VIRULENCE FACTORS: 
Staphylococcus aureus produces a diverse array of virulence factors 
including enzymes and proteins involved in surface adhesion and immune 
evasion. These factors facilitate the pathogenesis of this organism in different 
stages including colonization of a niche in the host, evasion and suppression of 
the immune response14. Based on virulence factors of Staphylococcus aureus 
five groups have been identified. 
 
Group 1: 
The enzymes released to lyse cells membranes to facilitate the spread of 
Infection of the host include  
1. Hemolysin (Hla) which lyses the cell membrane of blood cells. 
2. Hyaluronidase (HysA) which hydrolyses the hyaluronic acid present        
in the connective tissue.  
3. Staphylokinase (SAK) which breaks down fibrin clots. 
4. Lipases (Lip) which hydrolyze lipids on the surface of skin and in 
subcutaneous tissues in the host 15. 
 
Group 2: 
The surface factors are involved in colonizing host tissues and evading 
the immune system by inhibiting the phagocytic engulfment or disguising and 
modulating the immunological system. These proteins are covalently anchored 
to the cell wall peptidoglycan, thereby are called cell-wall anchored proteins 
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(CWA). There are 24 identified CWA proteins expressed by Staphylococcus 
aureus, however, their expressions depend on variable growth conditions. 
Recent reviews have proposed to categorise these CWA proteins into four 
groups based on their structural motif. These groups of CWA share a basic 
structure containing a signal sequence at the N-terminus, a wall-spanning 
region and sorting signal at the C-terminus but differentiate in specific 
additional regions. The sorting signal has a LPXTG sortase cleavage motif 
(Leu-Pro-X- Thr-Gly; where X is any amino acid), a hydrophobic domain and 
a charged tail, involved in covalent anchoring of the protein to the cell wall. 
Most of CWA proteins are involved in bacterial adhesion to different 
biomaterial surfaces and immune evasion whereas a subset of these promotes 
the formation of biofilm.  
In addition, these CWA proteins directly or indirectly interact with 
integrins and facilitate the invasion of non-phagocytic host cells. Intracellular 
bacteria can cause host cell apoptosis or necrosis, or they can enter a non-
disruptive semi-dormant state, including small colony variants (SCVs) 16. In 
addition, capsule production is the major surface factor contributing to the 
inhibition of phagocytosis. More than 90% of Staphylococcus aureus clinical 
strains have been shown to possess several types of capsular polysaccharides in 
which type 5 and type 8 are relevant in human infections. 
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Group 3: 
 The secreted proteins are involved in the suppression of immune cells 
(Immunoglobulins, complements or neutrophils) or in the inactivation of 
antimicrobial molecules (lysozymes, defensins). They include:  
1. Staphylokinase (SAK) which has been demonstrated to inhibit 
defensins and opsonophagocytosis. 
2. The innate immune modulators including chemotaxis inhibitory 
protein (CHIPS). 
3. The staphylococcal complement inhibitor (SCIN) which is employed 
to inactivate the human complements 17. 
4. O-acetyltransferase (OatA) released from the cell wall combining. 
5. Wall teichoic acids (WTA) which have been shown to play a role in 
deactivating host lysozyme activity. 
 
Group 4: 
 Toxins involving in septic shock include:  
1. Exotoxins (e.g. hemolysins with four different types - alpha, beta, 
gamma and delta - which all lyse the membrane of blood cells). 
2. Leukotoxin (LukSF), leukocidins (LukED-PVL) which kill 
polymorphonuclear leucocytes and macrophages and cause dermonecrosis. 
3. Enterotoxins (with eight antigenic types from A to H; responsible for 
food poisoning); enteroxtoxins SEA to SEG (EntA, EntB, SeA-G) act as 
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superantigens stimulating the proliferation of T-cells, these toxins are the 
leading cause for Staphylococcal gastroenteritis. 
 4. Toxic shock syndrome toxin (TSST-1) which causes a life-
threatening pathology characterized by fever, hypertension, vomiting, diarrhoea 
and erythematous rash. 
5. Exfoliative toxins (responsible for Staphylococcal scalded skin 
syndrome18.  
 
Group 5: 
 Bacteriocins are defined as antimicrobial molecules with a broad-
spectrum activity and involved in microbial competition with different species 
in colonization and infections. Staphylococcus aureus is able to produce 
several types of bacteriocins, in particular, a group of lantibiotics is well 
characterised. The lantibiotics are a group of ribosomal synthesised, post-
translationally modified peptides containing unusual amino acids, such as 
dehydrated and lanthionine residues. This group of bacteriocins has attracted 
much attention in recent years due to the success of the well characterised 
lantibiotic, nisin, as a food preservative.19  
Lantibiotics are defined as small peptides less than 5 kDa comprising of 
two main unusual amino acids lanthionine (Lan), L- methyllanthionine 
(MeLan) and a number of dehydrated amino acids such as the α, β- unsaturated 
amino acids Dha and Dhb 20. There are two groups of lantibiotics including 
Type A and Type B that can be differentiated by their structure and function. 
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Type A lantibiotics including epidermin, nisin, subtilin are characterised by the 
long peptide chains with 34 residues and damage the cell membrane of 
competitive organisms. Type B lantibiotics have a globular structure with 19 
residues and play a role in deactivating enzyme in cell wall biosynthesis. These 
exoproducts target other strains of Staphylococcus aureus, coagulase negative 
Staphylococci (S. epidermidis), Corynebacteria (C. pseudodiphteriticum) and 
Streptococci (S. pneumoniae). 
 
PATHOGENESIS:  
 Staphylococcus aureus is an opportunistic pathogen which only switches 
to be pathogenic under some circumstances. Some people are intermittent / 
persistent carriers of Staphylococcus aureus as a normal flora but others are 
not. Some individuals can carry Staphylococcus aureus for many years but may 
not develop disease. The higher risk of infection among persistent carriers than 
in intermittent and non-carriers has been previously described. Staphylococcus 
aureus infections occur when this organism invades the host and evades the 
host defence successfully, and this requires some initial steps such as 
inoculation and local colonisation of tissue surfaces. To survive in the host, 
Staphylococcus aureus must adapt to different stress factors such as nutrient 
limitation, desiccation, and changes in temperature, osmolarity and pH, 
competition from other bacteria as well as the antimicrobial actions of the 
human body21. 
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  The interactions among the host, bacteria and environmental factors 
contributing to the invasion of Staphylococcus aureus. Of these factors, the 
host factors are thought to play a key role and bacterial factors are thought to 
determine which strain is carried22. 
 
The interplay between bacterial, host and environment factors involved in 
Staphylococcus aureus colonization and infection. ( Peacock et al. 2001; Lowy 
2011) 
 
 
BACTERIAL FACTORS: 
 
Bacterial factors play an important role in colonisation and infections 
because some Staphylococcus aureus strains are observed in disease states 
more frequently than others. Bacterial factors are hallmarked by the diversity 
between Staphylococcus aureus genomes and the virulence factors, and factors 
specified for colonization and immune suppression. 
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GENOMIC FACTORS: 
 The Staphylococcus aureus genome varies from 2.5 to 3.1 Mb in size, 
and contains around 2,500 open reading frames. Numerous strains of 
Staphylococcus aureus have been sequenced such as N315 and Mu50, MW2 
MRSA252 and MSSA476, COL Newman, and the comparison data between 
these sequenced strains has shown a significant difference in some features 
among Staphylococcus aureus strains23. 
The in silico analysis on Staphylococcus aureus genomes revealed it consists of 
three main parts: 
1. Core genes (~ 80%, genes that have been highly conserved among isolates) 
encoding surface proteins promoting the Staphylococcus aureus adhesion and 
metabolic/regulatory proteins. 
2. Core variable genes (~10-12%, genes that vary or missing between 
genomes), encoding regulators of virulence genes or surface proteins involving 
in host interactions; 
 3. Mobile genetic elements (MGEs) (~10-20%, genes that can horizontally 
transfer among isolates) consisting more than 50% of virulence factors in 
Staphylococcus aureus including bacteriophages, pathogenicity islands, 
transposons, insertions, genomic islands, plasmid, etc.24. The MGEs allow the 
exchange of virulence factors and antibiotic resistance features among isolates, 
possibly resulting in new combinations of virulence factors and antibiotic 
resistance determinants. This issue may be responsible for the emergence of 
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new strains harbouring more virulent or more resistant combinations in the 
community. 
 The differences in genomic contents among the sequenced strains had 
been determined in the core genes but these are not as significant as in the 
MGEs region. The distinctive MGEs may support the versatile adaptation of 
strains specialised for the infection of selected host tissues25. 
 
HOST FACTORS: 
 The role of host factors in the outcome of Staphylococcus aureus 
infections have been extensively studied in different infections such as in 
rhinosinisitis, osteomyelistis, arthritis and endocarditis.26  These factors 
comprise numerous immunological cells which are involved in different stages 
of colonisation and infections such as neutrophils, macrophages, B cells, T 
cells, Natural Killer Cells, MHC Class II, interleukin-4, interleukin-12, 
complement factors, IFN-γ (interferon), TNF (tumour necrosis factor). These 
immune cells will act as the barriers to prevent the invasion of Staphylococcus 
aureus. In order to survive, this pathogen possesses numerous CWA proteins 
which are important for both adhesion and immune evasion.  
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Nasal colonisation and the functions of CWA proteins present in 
Staphylococcus aureus. (Nestle et al. 2009; Foster et al. 2014). 
 
During nasal colonisation, Staphylococcus aureus adheres to the 
epidermal cells which comprise 4 layers including stratum corneum, stratum 
granulosum, and stratum spinosum and stratum basale. The immune cells such 
as Langerhans cells in the epidermis and other cells such as natural killer (NK) 
cells, macrophages, T-cells, B- cells, mast cells, dermal dendritic cells and 
plasma cells in the dermis will act as the barriers to prevent the invasion of 
Staphylococcus aureus. This pathogen possesses numerous CWA proteins 
including several adhesion factors (blue background) as well as factors  
nvolved in immune evasion (purple background), and some factors which are 
important for both adhesion and immune evasion (orange background). These 
CWA proteins include CHIPS: chemotaxis inhibitory protein of 
Staphylococcus aureus, SCIN: Staphylococcal Complement Inhibitor; OatA: 
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O-acetyltransferase; SAK: staphylokinase; WTA: wall teichoic acid; SasG: 
surface protein G; SdrE, SdrD, SdrC: serine-aspartic acid repeat protein E, D 
and C; FnBPA, FnBPB: fibronectin-binding proteins A, B; ClfA, ClfB: 
clumping factor A, B; IsdA: iron-regulated surface determinant, AdsA: 
Adenosine synthase.27, 28  
 In recent investigations, there are specific host genetic factors that have 
been suggested to be important determinants for persistent nasal carriage and 
infections of Staphylococcus aureus in humans such as the presence of single 
nucleotide polymorphisms (SNPs) in the glucocorticoid receptor gene29,  the 
serine protease C1 inhibitor  as well as in interleukin-4. Furthermore, the skin 
damage, open wound, cuts and lesions as well as the physiological conditions 
of various niches (limited nutrients, limited oxygen, fluctuated osmolarity, pH, 
the presence of oxidative, nitrosative stress or other toxic agents) may facilitate 
the colonisation and infection of specific Staphylococcus aureus strains or 
contribute to the phenotype switching. 
 
ENVIRONMENT FACTORS 
Environmental factors increase the risk for carrying Staphylococcus 
aureus, as determined in numerous clinical reports, such as the crowding and 
the hygiene conditions in both health care facilities/professionals, and in 
household setting/family members. Moreover, pets/livestock might become 
reservoirs of Staphylococcus aureus and serve as intermediates in the 
transmission cycle30.  
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The interplay between bacterial factors, host factors and environmental 
factors seems to be crucial for the Staphylococcus aureus colonisation and 
infection process. Staphylococcus aureus has been previously known as an 
extra cellular organism, however, it also can be found to survive and persist in 
various host tissues including professional phagocytes and non professional 
phagocytes such as epithelial cells, osteoblasts31, endothelial cells, fibroblasts, 
and keratinocytes. This incredible ability of survival by this bacterium shows 
that Staphylococcus aureus is a versatile pathogen that can employ several 
strategies to be undetected by the host immune system or for inactivating the 
immune response by using a plethora of virulence factors related to 
colonisation, invasion and immune evasion. 
 
STAPHYLOCOCCUS AUREUS INFECTIONS AND DISEASES: 
 Staphylococcus aureus causes a wide range of illnesses through the 
body due to its capacity to colonize and grow in different kinds of host tissues. 
Anterior nares and skin are the frequent sites that Staphylococcus aureus 
colonizes as a harmless commensal organism but it can be also found in several 
body sites such as axillae, vagina and the gastrointestinal tract32. 
Approximately 20-25% of the human population are long term carriers, and 75-
80%  are intermittent carriers or non carriers of Staphylococcus aureus. 
However, the rate is higher among immune- compromised patients such 
as insulin-dependent diabetes, HIV- infected patients and patients undergoing 
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hemodialysis or skin damage conditions. The minor cutaneous infections 
caused by Staphylococcus aureus include carbuncles, boils, impetigo, burns, 
surgical site infections and wound infections. The more severe infections and 
life threatening infections such as sinusitis, tonsillitis, osteomyelitis, 
pneumonitis, endocarditis, meningitis, and bacteraemia occur when 
Staphylococcus aureus enters the body via an opening cut or wound. 
Additionally, by releasing the toxins on the food or in the blood stream, 
Staphylococcus aureus can also cause food poisoning, scalded skin syndrome 
and toxic shock syndrome33. 
 Clinical data have indicated that Staphylococcus aureus is the primary 
cause of lower respiratory tract infections and surgical site infections and the 
second leading cause of nosocomial bacteraemia, pneumonia, and 
cardiovascular infections. It is also the leading cause of primary septic arthritis 
and osteomyelitis in all ages except neonates34. However, in one global study 
spanning 100 hospitals in Canada, US, Latin America, Europe and West 
Pacific, Staphylococcus aureus has been demonstrated as the most prevalent 
cause of nosocomial bloodstream, skin and soft tissue infections (SSTIs) and 
pneumonia35. Staphylococcus aureus infections are usually developed in 
human by autoinfection – individuals being infected with their own colonising 
strains. However, individuals can acquire Staphylococcus aureus from other 
infected individuals via direct skin to skin transmission and nasal secretions or 
from environmental exposures such as humid conditions, public places, and 
lack of hygiene. The spreading of Staphylococcus aureus infections in the 
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community involving the CA-MRSA clones (community - acquired MRSA) 
whereas HA-MRSA clones (hospital-associated MRSA) dominate the health 
care facilities and pose both a huge financial cost and threat of serious infection 
for patients and the community36.  
Staphylococcus aureus contamination in the environment in hospitals 
(such as ventilators and bed ledges in intensive care unit) is  the major reservoir 
for crossing transmission between patients, medical devices and health care 
staff. The control of HA-MRSA infections is well managed in health 
professionals who are potential carriers of HA-MRSA. However, patients, in 
particular if immune-compromised, have a higher risk of infection (30-60%) 
and it remains near- impossible to clear or control the invading bacteria37. 
Staphylococcus aureus is also a known to colonise and infect both pets and 
livestock.  Staphylococcus aureus infection in humans is always a major 
concern but Staphylococcus aureus - infected animals (especially MRSA) 
could be the important reservoirs for human colonisation, leading to a potential 
pandemic.  
 
EPIDEMIOLOGY: 
 The emergence of infections associated with Staphylococcus aureus has 
been alarming mainly due to its resistance to multiple antibiotics. In US, the 
hospitalisation and mortality rate of the infections caused by Staphylococcus 
aureus is approximately twice the length of stay, deaths and medical costs of 
typical hospitalisations. Importantly, the MRSA rates have been increasing 
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rapidly worldwide during the last decades. Patients with MRSA infections have 
a 2.5-times higher average attributable death rate compared to MSSA 
infection38. Infections with Staphylococcus aureus are especially difficult to 
treat because of evolved resistance to antimicrobial drugs. Numerous clinical 
experts believe that the dissemination of MRSA through the community is as a 
result of unreasonable use of antibiotics in treatment, this selective pressure 
thereby leading to the rapid evolution of drug resistance in Staphylococcus 
aureus strains.  
The multi- drug resistant Staphylococcus strains currently known have 
become widespread in both healthcare facilities and the community and in both 
developed and developing countries. According to the SENTRY Antimicrobial 
Surveillance Program, between the years of 1997 and 1999, MRSA prevalence 
was 23% (of all Staphylococcus aureus strains) in Australia, 26% in Europe, 
32% in the USA, 35% in Latin America, 40% in South America, and 67% in 
Japan39. In one study in US, the death rates by Community - acquired and 
nosocomial Staphylococcus aureus infections were similar but Staphylococcus 
aureus - associated hospitalizations resulted in approximately twice the length 
of stay, and medical costs per patient40. 
 HA-MRSA infection is globally alarming because various HA-MRSA 
clones have spread worldwide and caused the high rate of morbidity and 
mortality. Indeed, a 2007 study in US estimated the number of deaths due to 
HA-MRSA infections in 2005 was 17,000 which surpassed those from AIDS. 
The cost of treating patients with MRSA is estimated between a $4 billion to 
 24 
$30 billion per year burden for the US economy41. One Canadian study stated 
the MRSA finance burden in Canada ranged from $40 to $59 million in 2000. 
Although HA-MRSA is an obvious concern recently, the CA-MRSA infections 
have been reported with increasing prevalence. A study performed in 
emergency departments in 11 cities in US found that 78% of the isolates were 
MRSA, and among these, 98% were the CA- MRSA USA300 strain, one of the 
most common strains of MRSA42. 
 
MOLECULAR BASIS FOR ANTIBIOTIC RESISTANCE: 
 From genomics studies, the acquisition of Staphylococcus aureus 
resistance in MRSA has been assigned to the presence of the gene ‘mecA’ 
located on the Staphylococcal chromosome cassette mec (SCCmec); a novel, 
mobile resistance element. The gene mecA encodes the 78-kDa penicillin 
binding protein 2A (PBP2A) which has a low affinity for β-lactam antibiotics 
leading to the inhibition of cell wall synthesis by inactivating transpeptidase. 
The regulation of mecA is controlled by the repressor MecI and the 
transmembrane β-lactam-sensing signal-transducer MecR1, which are both 
divergently transcribed. The integration of SCCmec into the genome is carried 
out with the cassette chromosome recombinases (ccr) genes including ccrA, 
ccrB and ccrC that are located on all SCCmec elements at a specific site. These 
genes excise and integrate at the SCCmec attachment site (attBscc) at the 3’ 
end of an open reading frame (orfX)43. 
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There are eleven subtypes of SCCmec from I to XI and six classes (A, 
B, C1, C2, D and E) performing different resistance patterns based on the 
arrangement of mec complex genes including mecA, regulatory genes mecI 
and mecR1 and with the insertion sequences44. Class A is identified with the 
presence of a complete mecR1 and mecI upstream and the variable regions and 
insertion sequence IS431 downstream of mecA. Class B is characterized by the 
presence of a truncated mecR1 (ΔmecR1) and insert sequence IS272 upstream 
whereas the variable regions and insertion sequence IS431 downstream. Class 
C is slightly different from Class B in that the presence of IS272 upstream is 
replaced by IS431. Based on the orientation of upstream and downstream 
IS431, there are two sub- classes C1 (same orientation) and C2 (reversed). 
Class D is different to Class C in that there is no presence of insertion sequence 
in the downstream region of ΔmecR1. One new arrangement has been 
classified as SCCmec type XI and class E in which mecR1LGA251 and 
mecILGA251 are located upstream of mecALGA251 and the blaZ gene is 
located downstream. 
 Recent articles have shown that CA-MRSA evolves independently from 
HA- MRSA. CA-MRSA strains usually have different subtypes of SCCmec 
(IV,V,VII), are often resistant to fewer antibiotic classes (frequently only β- 
lactams and macrolides), and are more virulent, with a high proportion carrying 
the genes encoding Panton -Valentine leukocidin (PVL). The presence of PVL 
is suggested as a feature to differentiate HA-MRSA and CA-MRSA, but this is 
still in question. Differently, HA-MRSA possesses the larger SCCmec subtypes 
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(I, II, III) containing multiple-drug resistance determinants, leading to slower 
growth rate than CA- MRSA due to the heavy metabolic burden associated 
with the large size of SCCmec. However, with the dissemination of CA-MRSA 
in hospitals, the distinction between CA-MRSA and HA-MRSA seems to fade. 
Currently eleven SCC mec types in Staphylococcus aureus strains based on 
their gene arrangements.45 
 
 
SCC mec type Ccr gene complex Mec gene complex 
I 1 (A1B1) B 
II 2 (A2B2) A 
III 3 (A3B3) A 
IV 2 (A2B2) B 
V 5 ( C ) C2 
VI 4 ( A4B4) B 
VII 5 ( C ) C1 
VIII 4 (A4B4)b A 
 
Classification of Staphylococcal Cassette Chromosome mec (SCCmec) 
Antimicrobial Agents and Chemotherapy, Dec. 2009, p. 4961–4967. 
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NOVEL BACTERIAL LIFESTYLES AS STRESS RESPONSES: 
To adapt to different environmental conditions outside and inside the 
host, some bacteria are capable of switching from their normal lifestyles to 
form quiescent phenotypes such as biofilms and SCVs. These quasi-dormant 
lifestyles have been characterized by a slower growth rate but with a prolonged 
survival capacity in the host both extracellularly and intracellularly when 
compared to planktonic cells. The existence of these alternative lifestyles in 
clinical settings of Staphylococcus aureus has been detected when the rate of 
chronic or relapse infections has drastically increased although the various 
antibiotic regimes have been applied46.  
Compared to the planktonic lifestyle of Staphylococcus aureus, biofilms 
and SCVs cells have been firstly revealed only since 1976 (biofilm) and since 
1955 (SCVs) in clinical settings. After some decades, an understanding related 
to the formation, the regulation, the pathogenesis as well as the detection and 
control of biofilm and SCVs is beginning to made, but there are still unclear 
and conflicting issues which require more investigation47. 
 
SMALL COLONY VARIANTS: 
 
 The development of novel lifestyles such as biofilm and small colony 
variants (SCVs) has been lately discovered as the main reasons for chronicity 
and relapse in Staphylococcus aureus infections. Several studies indicated and 
confirmed the crucial role of these switching lifestyles in clinical settings; in 
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particular, osteomyelitis, arthritis, rhino sinusitis, cystic fibrosis, soft tissue 
infections, sepsis, endocarditis and medical devices associated infections48. 
Infections involving either biofilm or SCVs are rarely resolved by host 
defences because in these states the pathogen is capable of surviving and 
developing a dormant state within various tissues. When suitable conditions 
arise the infections will recur unpredictably and often become more serious and 
even life threatening due to belated detection and treatment. These latent forms 
of Staphylococcus aureus have been causing a huge challenge for diagnosis 
and treatment, often resulting in higher rate of medical cost and mortality. 
Recent investigations have shown the role of Staphylococcus aureus 
biofilms and SCVs is central to relapsing infections. The estimated frequency 
of occurrence of human Staphylococcus aureus SCVs varies between 1 and 
30% of clinical samples. Staphylococcus aureus SCV was found in 29% of 
patients with osteomyelitis, 17–46% of patients with cystic fibrosis who were 
chronically colonised with Staphylococcus aureus49. There are several clear 
indications that cystic fibrosis, periodontitis, bloodstream and urinary tract 
infections result from Staphylococcus aureus biofilms indwelling medical 
device. The evolution in the lifestyle switching of Staphylococcus aureus has 
been extensively investigated and some understanding has been elucidated. 
However, various questions are still open regarding the formation, the 
regulation and related metabolic pathways as well as the pathogenesis of 
SCVs50. The key difficulty in the study of SCVs is that when cultured in the 
laboratory they revert to their parental growth-type. 
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BIOFILMS: 
Biofilms formed by bacteria have been described and researched for 
decades due to their increasing importance in pathogenesis. Originally, 
biofilms are known to cause industrial problems and now they are implicated in 
the spread of device-related and chronic infections. Bacterial biofilms can be 
isolated from mucosal or tissue samples of cystic fibrosis, native heart valve in 
endocarditis, as well as in otitis media, rhinosinusitis, tonsillitis patients and 
prosthetic devices such as central venous catheter tips, urinary catheter, and 
many other clinical situations. It is easily observed that these patients have 
optimal rough surfaces for biofilm attachment and growth51. Regarding 
pathological aspects, the planktonic form is often responsible for acute 
symptoms and systemic responses whereas biofilms cause chronic infections 
but acute exacerbations due to the complex latent immune sequela that they can 
provoke. 
Several pathogenic bacteria such as Pseudomonas aeruginosa, 
Streptcoccus pneumoniae, Hemophilus influenzae and Staphylococcus aureus 
are capable of biofilm formation that are clinically relevant. Numerous studies 
have indicated that there is a high prevalence of biofilm - mediated infections 
caused by Staphylococcus aureus. Importantly, its persistence and antibiotic 
resistance, have widely been reported in clinical outcomes worldwide. A recent 
study over a large number of clinical isolates has revealed that the strains with 
greater multi-resistance to antimicrobial compounds have significantly 
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increased their ability for biofilm formation rather than those with less 
resistance 52. 
 
DEFINITION AND FORMATION OF BIOFILMS: 
According to the current definition, biofilms are characterized by 
heterogeneous Multi - layers of sessile single cells and micro-colonies, which 
are encased in a matrix of extra cellular polymeric substances (EPS). This 
matrix is possibly composed of intercellular polysaccharide adhesions (PIA) 
and proteins along with extra cellular genetic materials (such as extra cellular 
DNA). These layers cover and attach to a substratum, interface or to each other 
persistently and thereby establishing a recalcitrant block to resist external 
destructive factors. Within biofilms, there are four distinct metabolic states of 
growing cells including aerobically (often located in the outmost layers 
exposed to oxygen and nutrients) fermentative, dormant and dead in which the 
dormant cells are dominant and lodge in the anoxic layers 53.  
The changes in cell-type due to the phenotypic change, the altered 
growth rate as well as the expression of genes related to the cell’s metabolic 
pathways, surface structures and virulence factors have all been well- 
documented. The formation of biofilms has been proposed to consist of four 
phases namely attachment, accumulation, maturation, and dispersal. 
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Attachment and Accumulation 
 In the first stage, the attachment of planktonic cells depends on the 
surface appendages. The presence of high sheer forces, for instance, in mucous-
covered surfaces, will promote the initiation of biofilm formation. In the stage 
of aggregation, the surface factors including a variety of CWA proteins and 
extracellular DNA (eDNA) and teichoic acids (TA) have been shown as crucial 
components for the bacterial adherence for Staphylococcus aureus. When the 
adjacent cells interact, the structure of some CWA proteins (fibronectin-
binding proteins (FnBPs) and SasG) may be modified and twist around each 
other or these can bind to other ligands on neighboring cells to promote the 
aggregation of cells54. 
 
Maturation 
 
 When a number of cells are grouped and bonded based on the change in 
their cell wall structures. The main molecule responsible for the aggregation in 
Staphylococcus aureus is polysaccharide intercellular adhesin (PIA), which 
composed of N- acetylglucosamine residues; 20% of the residues are 
deacetylated and are thus positively charged. However, PIA-mediated biofilms 
is not unique, some strains isolated from biofilm- associated infections do not 
have the ica genes. In these PIA-independent biofilms, the cell wall–anchored 
proteins (CWA) are more relevant. In a maturation stage, biofilm structure has 
been described as “towers” or “mushrooms” containing a system of fluid-filled 
channels which is believed to be responsible delivering nutrients to cells to 
 32 
deeper layers. Nevertheless, the most recent publication has revealed that the 
eDNA released from lysis cells is a predominant component in biofilm 
maturation of Staphylococcus aureus 54. As a polyanionic molecule, eDNA 
plays an important role in shaping the matrix is due to the capacity to link other 
ingredients together and facilitate the biofilm adhesion to surface well. 
 
Dispersal 
 
As the biofilm is completely developed, single cells or small clusters of 
cells are able to detach from the mature biofilm and reallocate to other distant 
sites. The mechanisms involved in the dissemination of biofilms are still 
unclear. The biofilm dispersal is probably relevant for the spread of biofilm-
associated infections and these issues can be observed in clinical cases such as 
endocarditis (bacterial detachment from biofilms on heart valves), pneumonia 
(bacterial dispersal from biofilms from endotracheal tube / oropharynx) or 
sepsis55.  
 
Some significant features for dissemination have been recently 
uncovered, including extracellular bacterial products which degrade and 
solubilise the adhesive component of the matrix, environmental conditions, and 
polymicrobial interactions. Indeed, the production of extracellular enzymes 
(DNAses, proteases) and surfactants (phenol soluble modulins - PSMs) have 
been indicated as the primary factors which promote the detachment of 
bacterial cells from biofilm matrix. The deletion of the genes encoding the 
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proteases and the addition of protease inhibitors both resulted in a significant 
increase in Staphylococcus aureus biofilm formation. Similarly, the nuclease-
deficient mutant strains of Staphylococcus aureus and the addition of DNases 
exhibited significantly increased biofilm formation, indicating that eDNA is a 
major part of the biofilm matrix. In addition, PSMs have been demonstrated to 
promote biofilm disassembly in vitro and promote the bacterial dissemination 
from colonised catheters in a mouse model of device-related infection. PSMs 
are surfactant-like peptides due to their amphiphilic helical structures that are 
regulated by the agr quorum-sensing system55. So far little detail is known 
about the impact of environmental conditions and polymicrobial interactions on 
biofilm dispersal. 
 
The accessory gene regulator (agr) quorum-sensing system is involved 
in dissemination of bacterial cells from biofilms. When the biofilm is mature, 
the presence of auto-inducingbpeptides (AIPs) throughout the bacterial 
community can reach a quorum sensing thresholdband leads to the induction of 
the expression of agr. The up-regulation of agr induces the formation of PSMs, 
protease and nuclease expression, leading to the detachment of planktonic cells 
out of biofilm matrix to relocate in other host tissues. The agr mutants formed a 
thicker and more compact biofilm in vitro compared to isogenic wild-type 
strains56. Most likely, the permanent disabling of agr regulation and the 
consequent excessive biofilm formation are of advantage to bacterial survival 
in specific stages or types of infection. Notably, mutations that produce agr- 
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negative phenotypes are common and can also be seen in vitro where they 
occur at a high rate. 
 
In general, during infections, the early step of accumulation and 
attachment is a prerequisite for the bacterial colonisation on host niches or 
tissues or on implanted and prosthetic medical devices, whereas the final 
detachment is a crucial role for the dissemination of an infection. In addition, 
the composition of biofilm matrix is possibly variable among the 
Staphylococcus aureus strains; it seems to rely on various environmental 
conditions of host tissues or niches with changeable physiological and physical 
conditions as well as the availability of nutrients. The role of PIA in the 
Staphylococcus aureus biofilm matrix is still an area of some conflict as some 
studies indicated that it is not crucial for the development of biofilm compared 
to the results from previous studies. The understanding of the complexities of 
the Staphylococcal biofilm matrix remains incomplete and requires more 
research in the future. 
 
DEFINING CHARACTERISTICS 
 Staphylococcus aureus SCVs have a distinct phenotype which is 
characterized by a slow growth rate and atypical morphological and 
biochemical properties compared to the parental phenotype. Therefore, SCVs 
have just been defined after incubation after 48 or 72 hrs to form visible 
colonies on the solid agar plates. Their size of colonies are very small as pin- 
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point, or can be defined as less than 1/10th in size compared to normal size of 
Staphylococcus aureus colonies. In addition, the pigment of colonies is 
significantly reduced or colourless an their hemolysis is greatly reduced or 
negative. 
 
Recent research have added a variety of new characteristics for SCVs, 
however, these findings may only be indicative for SCVs recovered from the 
specific strains or isolates within those studies. According to some authors, 
SCVs are auxotrophic for hemin, menadione and/or thymidine and an altered 
ability to utilise different carbon sources such as glucose and fructose but not 
able to use mannitol or other sugars such as turanose and lactose. Other reports 
showed that SCVs have reduced coagulase production and require more than 
18 hrs of incubation to be coagulase positive. SCVs have been often 
represented in a mixed population with normal S. aureus, furthermore, SCVs 
may revert to the (wild type) WT when growing together in the rich medium 
without adding antibiotics, this causes Staphylococcus aureus SCVs to be 
frequently unidentified. In addition, the slow growth rate may affect the 
diffusion test or other antibiotic susceptibility tests, leading to the 
misidentification when using standard clinical microbiology procedures 57. 
 
 
 
 
 36 
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 
In the year 1942, the first penicillin resistant Staphylococcus aureus was 
identified. All the resistant strains become pandemic in early 1950s.Resistance 
to Methicillin and vancomycin developed in most strains of Staphylococcus 
aureus is mediated by mecA and van A genes respectively. They are also 
resistant to β- lactam antibiotics and classes of antibiotics. European hospitals 
reported MRSA infections that caused an outbreak during early 1960s. About 
25% of nosocomial infections in health care institutions are caused by MRSA 
infections in US with half of associated deaths. High mortality has also been 
associated with MSSA that caused death mainly due to septicaemia. In spite 
use of appropriate chemotherapy most of serious sequalae are due to MRSA 
than MSSA and overall mortality rate continues to rise.  
The transmission of bacteria takes place by carrier colonized with 
bacteria, IV drug addicts, Insulin dependant diabetes and those with 
intravascular catheters for prolonged period constitute high risk group. Higher 
colonization rate has been observed in children due to their frequent contact 
with respiratory secretions. Emerging MRSA strains confined not only to 
hospital but they also appear in community due to inappropriate use of 
antibiotics which caused overgrowth and increased pathogenicity of the 
organism.  
Due to evolutionary changes and epidemiological expression of the 
MRSA strains, new MRSA strains have now emerged which differ from the 
initial isolates Beyond antibiotics the ability of the organism to adapt to the 
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environment and advances in patient care causes MRSA emerging as a major 
pathogen not only in hospital but also in community. Person to person 
transmission has been reported in CA-MRSA infection hence it is associated 
with higher morbidity and mortality. The knowledge of circulating MRSA 
clones under the prevailing scenario can be helpful in controlling transmission 
and optimizing treatment58.  
After 1990s people who were not hospitalised but undergone invasive 
procedure MRSA has become a matter of great concern. Infections caused by 
such strains are called as CA MRSA. High risk populations such as intravenous 
drug users, patients in nursing homes, chronically ill person, CA MRSA first 
reported but also found in healthy children. Till recently these strains are 
sensitive to all antibiotics other than b lactams but now resistance to most of 
the antibiotics has emerged. The clonal lineages of Staphylococcus aureus have 
tendency to colonize specific species and may adapt either human or animals. 
The more prevalent epidemic strains are capable of spread with in hospital or to 
other places outside but the sporadic stains spread widely. Extended host 
spectrum genotypes have appeared which have different lineages, host 
specificity and tendency to infect wide range of species.  
For example MRSA ST22-IV, EMRSA15 have been reported in pigs 
(rarely), turtles, bats, cats, dogs, and humans59. In US hospitals, most 
commonly identified antibiotic resistant pathogen is MRSA and 25.9% of 
Staphylococcus aureus strains isolated from out patients were methicillin 
resistant (National infectious surveillance system report, 2003). Most of these 
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strains were isolated from persons who acquired them from healthcare 
environment.60   
The MRSA is defined by presence of mecA and antibiotic susceptibility 
is used by some researchers.to identify it. A genetic evolutionary analysis 
demonstrated that the mecA gene has been transferred into methicillin-
susceptible Staphylococcus aureus (MSSA) more than 20 times and emerged in 
more than 5 phylogenetically different lineages as well as re-emerged within 
individual lineages. The introduction of the mecA gene from putative donor 
species into MSSA strains which are already adapted successfully to the 
hospital environment and to the community, created successful epidemic HA-
MRSA and CA-MRSA clones. It is believed that ancestral MRSA genotypes, 
ST250- MRSA originated in Denmark which possesses SCCmec type I, were 
recovered in the 1960s.  
This genotype arose as it acquired the mec gene by ST250-MSSA, 
which itself had arisen from ST8-MSSA by chromosomal point mutation61. 
ST250-MRSA evolved by a single point mutation, an important hospital 
pathogen in Europe and has been reported to cause outbreaks in New York 
hospital. The emergence of CA-MRSA strains has repeatedly occurred as a 
result of the introduction of SCCmec type IV into a different genetic MSSA 
background. MDR usually seen in HA-MRSA strain and antibiotic resistance is 
limited to beta-lactams in CA-MRSA. The size of SCCmec type IV is small 
which prevents its carriage of additional genetic material, in contrast to the 
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characteristic presence of additional genetic material in SCCmec type II and 
SCCmec type III. 
 
INTRODUCTION TO FLUOROQUINOLONES: 
In 1960s Nalidixic acid was used a drug of choice for most of Gram 
negative bacteria but it is less effective  on Gram positive bacteria and frequent 
daily administration and tendency to cause photosensitivity reactions and 
convulsions limited its use. 
In mid 1980s introduction of norfloxacin followed by ciprofloxacin was 
a major improvement over Nalidixic acid. The advantage of twice daily 
administration and ability to obtain high concentrations in tissues and fluids 
with high clinical efficacy with excellent activity against Gram negative and 
some action on Gram positive bacteria made it as a good drug. 
The new fluoroquinolones have a substituent of carboxylic acid at 
position 3 and at position 4 have a carboxyl group which helps in transport into 
bacterial cells and attachment to the DNA gyrase complex which are 
significantly done by these groups. 
In vitro potency, mostly against Gram-positive bacteria is almost 
determined by the amino substituent at position 5 of the quinolone ring , as 
found in sparfloxacin. Grepafloxacin enhances potency against Gram positive 
bacteria because of presence of methyl group at C-5 to a lesser extent. A fluoro 
substituent, present at C-6 position in all new fluoroquinolones is responsible 
for fluoro nomenculature and increases antibacterial potency62. 
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The presence of piperazine ring at position 7 increases efficacy of 
fluroquinolones against Gram negative organisms (eg: ciprofloxacin, 
gatifloxacin, grepafloxacin, levofloxacin and sparfloxacin) and pyrrolidine ring 
at the same position enhance activity on Gram positive bacteria alkyl group of 
both ring type  increases solubility prolongs the half life and excellent action on 
Gram positive bacteria, Ciprofloxacin and grepafloxacin interact with 
theophylline because of presence of non bulky side chains at C-7. 
  Presence of halogen at position 8 widens the spectrum of antibacterial 
activity and extends action on anaerobes in sparfloxacin and clinafloxacin 
similarly methoxy subsitituent at position 8 in gatifloxacin and moxifloxacin 
enhance activity on anaerobes.  
 
MECHANISM OF RESISTANCE TO FLUOROQUINOLONES: 
 
The enzymes topoisomerase and gyrase control DNA levels and play 
important role in nucleic acid processes. They pass an intact double helix via 
separate segment of DNA by generating a transient double stranded break.The 
two distinct functional subunits of Gyrase and topoisomerase are gyrA and 
gyrB and homologous subunits grlA and grlB respectively in Gram positive 
species63. 
The active site that is present in gyrA is tyrosine residue. gyrB has the 
ATPase domain and also TOPRIM domain, both of them binds the divalent 
metal ions that are responsible for DNA cleavage and ligation. Gyrase and 
topoisomerase IV have different functions of introducing negative super coils 
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inside the DNA physiologically in spite of their structural similarities gyrase 
belongs only to type II topoisomerase. The ω protein (a type I topoisomerase) 
combines and works with gyrase to form the super helical density of the 
bacteria chromosome. The torsional stress is removed primarily by the gyrase 
enzyme.  
Chromosomal superhelical density and alleviating torsional stress is less 
commonly maintained by topoisomerase IV than gyrase and taking away the 
knots from the bacterial chromosome due to basic cellular process removing 
daughter chromosomes as a result of replication is the major function of this 
enzyme. 
In Staphylococcus aureus the  flouroquinolone  resistance mechanism is 
mainly due to  substitutions  of aminoacid at particular locations in the DNA 
gyrase A and B subunits as well as in the topoisomerase IV  subunits and also 
from norA mediated efflux .In a single strain more than one resistance 
mechanism can be present64. 
 
Disk diffusion method by Kirby Bauer Method: 
The sensitivity or resistance of pathogenic aerobic and facultative anaerobic 
bacteria to multiple antimicrobial compounds is determined by the Kirby-Bauer 
disk diffusion susceptibility test. Mueller-Hinton agar is used to grow the 
pathogenic organism in the presence of various antimicrobial impregnated filter 
paper disks.  The ability of the antibiotic to inhibit growth is determined by 
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presence or absence of growth around the disk. A filter paper disk of about 
6mm is placed on Muller Hinton agar plate. The water present on the disk will 
be absorbed immediately65. The antibiotic starts to diffuse in to the medium 
and the concentration will be more near the disk it reduces gradually away 
from the disk. It depends mainly on molecular weight and solubility properties 
of the drug. 
 
AGAR DILUTION 
Many researchers use agar dilution method to decide the resistance of 
most pathogenic organisms to antibiotics. It is the commonly used dilution 
method to check the efficacy of new antibiotics.  
 
Process 
The agar is mixed with antibiotic to be evaluated and then it is added to 
dilution plates and diluted with different levels of water. Afterwards the disease 
causing organism to be tested is supplemented to each agar plate and an 
additional control plate that does not have any antibiotics. The dilution plates 
are incubated for sixteen to eighteen hours at a temperature of 37 degrees 
Celsius. Bacterial populations that divide quickly can be incubated for lesser 
time.   
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The plates are tested for bacterial growth after incubation. The extent of 
spread of bacteria that can be stopped by the lowest concentration of antibiotic 
is taken as the minimum inhibitory concentration of that bacteria66.   
 
Advantages 
The most correct way to determine the antibiotic resistance of bacteria is 
Agar dilution method and it is the gold standard of susceptibility testing, many 
samples up to thirty pathogens can be tested at once. The results are easily 
monitored and can be reproduced. 
 
Disadvantages 
In agar testing every dilution plate infected by the pathogenic organism 
to be tested so agar dilution testing is cost effective and labour intensive. Agar 
dilution can be used to test only one antibiotic at a time but in broth micro 
dilution tests more than one antibiotic can be tested67.  
 
TREATMENT 
 Drug resistance in Staphylococcus aureus developed rapidly, so the antibiotics 
should be used judiciously to prevent resistance. For methicillin sensitive 
Staphylococcus aureus the first line drugs remain the treatment of choice, while 
for MRSA vancomycin and linezolid need to be given. Teicoplanin,  daptomycin 
and quinupristin / dalfopristin could be alternate choices. Patients who colonise 
MRSA in the anterior nares should be treated with Mupirocin topical application 
twice a day for five days.  
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CONTROL MEASURES 
To prevent hospital spread of Staphylococcus aureus hand washing is 
the most important step. Health care workers should be periodically 
screened for MRSA carriage and treated appropriately. Antibiotic usage 
should be restricted and preauthorization for high end antibiotics should 
be obtained prior to treatment. This will ensure misuse of antibiotics.  
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AIMS AND OBJECTIVES 
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• To detect phenotypic and genotypic resistance among Staphylococcus 
aureus 
• Isolation and characterisation Staphylococcus aureus from clinical 
isolates. 
• Disk diffusion and Agar dilution sensitivity methods for detection of 
Quinolone resistance. 
• Detection of gyrase and topoisomerase genes from representative 
samples. 
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 MATERIALS AND METHODS 
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STUDY POPULATION 
 
Isolates obtained from various clinical samples received at the Diagnostic 
  
 Microbiological laboratory, PSG Hospitals, Coimbatore. 
 
STUDY LOCALE: 
 
PSG Hospitals Coimbatore 
 
STUDY PERIOD: 
 
April 2016 - July2017 
 
SAMPLE SIZE ESTIMATION: 
 
N= 4pq/d2 
 
Where n is required sample size p is expected prevalence q is 100-p and d is 
 
 Degree of prevalence 
 
 
SAMPLING METHOD: 
 
Convenience sampling 
 
TYPE OF STUDY: 
 
Cross sectional prospective study 
 
 
ETHICAL CLEARANCE 
 
 
This study was undertaken in the Diagnostic Microbiology Laboratory 
 
 Department of Microbiology, PSG Hospitals. Institutional Human ethical 
 
 Clearance was obtained, proof of which has been attached. 
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METHODOLOGY – FLOW CHART 
 
 
 
 
Detection of flouroquinolone resistance in Staphylococcus 
aureus from various clinical samples 
 
Culture on blood agar, showing beta haemolytic golden yellow 
colonies and Mac Conkey agar showing small lactose fermenters 
(SLF)showing small lactose fermenting colonies 
 
Catalase test 
Tube coagulase test 
Mannitol fermentation 
Detection of flouroquinolone resistance 
Phenotypic  
Methods 
Genotypic  
Methods 
Disk Diffusion 
Method & Agar dilution 
Method 
Detection of gyrase (gyrA, 
gyrB), topoisomerase IV 
(grlA, grlB) genes by Real 
time PCR 
Identification of Gram positive cocci in clusters from cultures 
 
Bio chemical tests 
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SAMPLE COLLECTION: 
 
All clinical samples which were sent to diagnostic microbiology 
laboratory were included in the study. Around 120 clinical isolates of 
Staphylococcus aureus from various clinical samples such as blood, wound 
swab, pus, sputum, broncho -alveolar lavage, tracheal aspirate, which grew 
beta haemolytic golden yellow colonies on 5 % sheep blood agar were 
processed. 
 
SMEAR MICROSCOPY:  
GRAM’S STAINING PROCEDURE: 
• Slides were arranged and kept in serial order on the staining bridge one 
after another. 
• Primary staining was done by crystal violet. The filtered stain was added 
on entire surface of the slide and kept for one minute.  
• The slide was washed with water. In second step Lugol’s iodine was 
added which act as mordant and kept for one minute. 
• The slide was washed with gentle stream of water and was tilted to drain 
off excess water 
• Decolourisation was done with Acetone with in ten seconds. 
• The smear was counterstained by covering the entire surface of the slide 
with dilute carbol fuschin for thirty seconds 
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• Slide was rinsed with water to drain off the counter stain and under side 
of the smear was wiped. 
• Slide was placed on the slide rack to air dry. After drying they were 
examined under microscope. 
 
SMEAR EXAMINATION: 
 A drop of emulsion oil placed on the dried smear without touching the 
slide. The smears were examined with the 100 x oil immersion objective. 
Both positive and negative controls were put on the same slide. Positive 
controls from ATCC Staphylococcus, negative controls from ATCC 
Escherichia coli were satisfactory. Gram positive cocci in clusters were 
observed and identified as Staphylococcus.  
 
CULTURE CHARACTERS:  
 All processing work was done in bio safety cabinet class II type A2 
under strict aseptic precautions. Clinical samples were streaked on plates 
with 7% sheep blood agar and Mac Conkey agar.  All culture plates were 
incubated at 35 to 370 C up to 24 – 48 hours. 
 
CULTURE EXAMINATION: 
 Cultures were examined after 48 hours of inoculation to detect growth. 
Blood agar plates were observed for the growth of beta haemolytic golden 
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yellow colonies. The Mac Conkey agar was examined for small lactose 
fermenting colonies without any contamination.  
 
BIO CHEMICAL TESTS: 
CATALASE TEST: 
 The presence of catalase enzyme was detected in the test isolate 
using hydrogen – peroxide.  
 
Principle: 
 Catalase is an enzyme is produced by most of the aerobic and 
facultative anaerobic micro organisms to neutralize toxic forms of oxygen 
metabolites. It neutralizes bactericidal effects of hydrogen peroxide and 
protects the bacteria. This enzyme is absent in anaerobes.  
 The breakdown of hydrogen peroxide is mediated by catalase 
into oxygen and water. All the aerobic bacteria respire by using oxygen as a 
electron acceptor.  
 
Procedure of Catalase Test: (Slide test) 
1. A loop or sterile wooden stick was used to transfer a small amount of 
bacterial colony to the surface of dry, clean glass slide.  
2. A drop of 3% H2O2 was placed on the slide and mixed with the 
bacterial colony.  
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3. A positive result was interpreted by rapid evaluation of oxygen 
within 5 – 10 Seconds as evidenced by bubbling. 
4. The slide was disposed in the biohazard disposal container. 
 
 Procedure of tube Catalase Test: 
1. A test tube was added with 4 to 5 drops of 3 % H2O2. 
2. A small amount of organism was transferred to the test tube with 
wooden applicator.  
3. The test tube was placed against dark background and observed for 
immediate bubble formation at end to wooden applicator.  
 
TUBE COAGULASE TEST: 
          This is used to differentiate between Staphylococcus aureus and 
coagulase negative Staphylococcus CONS. 
 
Principle of the Test 
The staphylocoagulase produced by the Staphylococcus aureus reacts 
with coagulase reacting factor which is a thrombin like molecule. They both 
combine to indirectly convert fibrinogen to fibrin and gives positive result. 
 
Procedure:  
        Human plasma was diluted in saline as 1 in 6 dilutions and one ml volume 
of this diluted plasma was placed in small tubes. Several isolated colonies of 
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Staphylococcus aureus were emulsified in the plasma to get a milky 
suspension. All tubes were incubated at 370 C for 4 hours. All tubes were 
examined for clot formation by tilting the tube at 900   at end of 4 hours 
incubation. The negative tubes were left at room temperature over night and re-
examined. This step was essentially done because some strains including many 
MRSA produce a delayed clot which was rapidly lysed by staphylokinase 
produce by organism. The positive result was interpreted by clot formation. 
Appropriate positive and negative controls were put. 
 
ANTIBIOTIC SENSITIVITY PROCEDURE: 
Kirby Bauer disc diffusion: 
 The peptone water was inoculated with the test organism and incubated 
for four hours at 370C. The turbidity was matched with 0.5 Macfarlands. A 
sterile swab was soaked in the inoculum and squeezed against the wall of the 
test tube and was spread over the Muller – Hinton agar plate. Antibiotic discs 
like Vancomycin ( 30 µg ), linezolid ( 30 µg), Amoxy-clav ( 30 µg ), 
Clinadamycin ( 2 µg ), Erythromycin ( 15 µg ), Penicillin ( 6 µg ), 
Ciprofloxacin ( 5 µg ), Levofloxacin (5 µg ), Ofloxacin ( 5 µg) were placed on 
the MHA plate and tested for sensitivity pattern. A cefoxitin 10 µg disc was 
placed over the MHA plate and incubated at 37 0C for 24 hours. Next day zone 
size was measured. A zone size of > 22mm was interpreted as Methicillin 
sensitive Staphylococcus aureus (MSSA) and less than 22 mm was considered 
as Methicillin resistant Staphylococcus aureus (MRSA)  
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 The zone diameter of fluroquinolones like Ciprofloxacin, Ofloxacin. 
Levofloxacin with appropriate disc strength was interpreted as follows 
FLUOROQUINOLONES Staphylococcus species.   
 
 
 
Antimicrobial 
agent 
Disk 
content 
SENSITIVE INTERMEDIATE RESISTANT 
Ciprofloxacin 5µg ≥21 16-20 ≤15 
Levofloxacin 5 µg ≥19 16-18 ≤15 
Ofloxacin 5 µg ≥18 15-17 ≤14 
 
CLSI guidelines for Antimicrobial susceptibility testing – 2016 
 
Testing of MIC by Agar Dilution Method. 
  
MIC was done by agar dilution as per the (CLSI-2013) guide lines. The 
materials used for the agar dilution were Mueller Hinton agar, Pure 
pharmaceutical products of antimicrobial powder, petriplates, pipettes, 
antimicrobial solvents, disposable tips, sterilized test tubes etc. The 
antimicrobial agents used for testing were Ciprofloxacin, Levofloxacin, and 
ofloxacin for the species Staphylococcus aureus. 
 
Preparation of drug dilutions  
The drug dilutions are prepared according to the CLSI guide lines (M26-
A) by agar dilutions methods. The table describes drug dilution protocol as per 
CLSI Guidelines 
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Preparation of stock solution of antibiotic solution 
 
 
Stock solutions are generally prepared by using this formula: 
 
    1000    
         x V x C  = w 
      P 
 
Where 
 
P= potency given by the manufacturer in relation to the drug 
 
V= volume (ml) required 
 
C= final concentration of the solution 
 
W= weight of the antibiotic to be dissolved in the required volume. 
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1 5120 Step 1 1ML 3 ML 1280 64 
2 1280 Step 1 1ML 1ML 640 32 
3 640 Step 2 1ML 1ML 320 16 
4 320 Step 3 1ML 1ML 160 8 
5 160 Step 4 1ML 1ML 80 4 
6 80 Step 6 1ML 1ML 40 2 
7 40 Step 7 1ML 1ML 20 1 
8 20 Step 8 1ML 1ML 10 0.5 
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PREPARATION OF INOCULUM:  
The inoculums were prepared from fresh subculture of Staphylococcus 
aureus isolates by using a sterile inoculation loop by picking 4 to 5 similar 
colony in to the sterile saline. 
The suspensions were matched to McFarland 0.5 turbidity standard 
(approximately 1.5× 108 CFU/ml). The working dilutions were made further by 
diluting 25 times in to CAMHB (Cation-adjusted Mueller-Hinton broth)   to 
obtain a final organism concentration of 3× 105 to 5× 105 CFU/ml in each. 
 
Procedure: 
• The drugs diluted were prepared from higher to lower as mentioned in 
the table in the test tubes. This diluted drug solutions were mixed in to 
20 ml of media.  The final concentrations were achieved 64µg/ml after 
mixing in to 20ml of media. Similarly other concentrations also made to 
achieve 32µg, 16µg, 8µg, 4µg, 2µg, 1µg, 0.5µg as follows. 
• Drug free control plates were prepared without adding drug in to the 
medium.  
• Before inoculation of culture in to the medium the plates was divided 
Column and Marked for identity on backside of plate. 
• 1μl of inoculum that were transferred from prepared inoculum of 104cfu 
/ml by dilution in to medium of appropriate Column. 
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• Different isolates were inoculated in to different labeled Column.  
• The plates were incubated at 37 ℃ for 18- 20 hours. 
Interpretation of MIC: 
• The results were interpreted by checking Growth on drug free 
medium, control plate showing satisfactory growth. 
• The MIC was calculated by the inhibition of visible growth in 
least concentration of each isolate in particular concentrations 
were considered MIC of Each isolate.  
Antimicrobial 
agent 
MIC(µg/ml) 
SENSITIVE 
MIC(µGg/ml) 
INTERMEDIATE 
RESISTANT 
Ciprofloxacin ≤1 2 ≥4 
Levofloxacin ≤1 2 ≥4 
Ofloxacin ≤1 2 ≥4 
 
CLSI guidelines for Antimicrobial susceptibility testing – 2016 
 
 
Genotypic Method for detection of Fluroquinolone resistance 
The DNA purification procedure using the miniprep spin columns 
comprises of three steps  
  1. Adsorption of DNA to the membrane. 
  2. Removal of residual contaminants. 
  3. Elution of pure genomic DNA.  
Principle 
 Bacterial cells are grown in a medium till they reach log phase and are 
harvested by centrifugation. The bacterial (Gram positive) cell wall is degraded 
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by lysozyme and Proteinase K. For Gram negative bacteria, the lysozyme 
treatment is not required. Following lysis, the DNA is bound to the silica-gel 
membrane of the HiElute Miniprep Spin Column (Capped) to yield 
approximately upto 20µg of pure DNA. Two rapid wash steps remove trace 
amount of salt and protein contaminants resulting in the elution of pure DNA in 
the Elution Buffer provided with the kit.  
Reagents provided (HiPurA Bacterial Genomic DNA Purification Kit) 
 Gram Positive Lysis Solution (GPLA)  
 Lysis Solution (AL)  
 Lysis Solution (C1)  
 Prewash Solution (PWB)  
 Wash Solution Concentrate (WS)  
 Elution Buffer (ET) [10 m M Tris - Cl, pH 8.5]  
 Proteinase K  
 RNase A Solution (20 mg/ml)  
 Lysozyme  
 HiElute Miniprep Spin Column (Capped)  
 Collection Tube(Uncapped) , Polypropylene (2.0 ml)  
 Collection Tube, Polypropylene (2.0 ml) 
Procedure: 
1. An overnight bacterial broth culture was pelleted in to a 2 ml capped 
collection tube of about 1.5 ml and was centrifuged for 2minutes 
13,000 rpm at room temperature ( 15 – 250C). 
 60 
2. 200µl of Lysozyme Solution was added for each isolate and  
Incubate at 37°C for 30 minutes. 
3. The Pellet was resuspended thoroughly in 180µl of Lysis Solution. 
4. 20µl of the Proteinase K solution was added to the sample mixed and 
was incubated for 30 minutes at 55°C. 
5. 200µl of Lysis Solution (C1) was added vortexed thoroughly (about 
15 seconds) and incubated at 55°C for 10 minutes. 
6. 500µl of prewash Solution was added to the column and centrifuged  
at (≈10,000 rpm) for 1 minute at room temperature. 
7. 500µl of diluted Wash Solution (WS) was added to the column and 
centrifuged for 3 minutes at 13,000 rpm at room temperature (15-
25°C). Discarding the flow through was done and has been spin 
again at same speed for the additional 1 minute to dry the column. 
8. Transferring of the HiElute Miniprep Spin Column (Capped) to fresh 
uncapped collection tube was done. Pipette 200µl of the Elution 
Buffer (ET) directly into the column without spilling to the sides and 
incubated for 1 minute at room temperature and then centrifuged at 
(≈10,000 rpm) for 1 minute at room temperature (15-25°C) to elute 
the DNA. 
9. Transferring of the eluate to a fresh capped 2ml collection tube was 
done for longer storage at – 20°C. 
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DNA Amplification 
      The extracted DNA from the isolates were amplified  by using Real time 
PCR = AB  Applied bio systems 
Sterile 1.5 ml tubes were taken for the preparation of PCR 
Master mix = 12.5 Microlitres, PCR water 8.5 Microlitres 
DNA  lysate 2 Microlitre 
Target Primer Sequence 5’ to 3’ Expected Amplicon 
size(bp) 
grlA- 
 
Forward 
primer 
 
 
Reverse 
5’-TGC CAG ATG TTC 
GTG ATG-3’ 
 
 
5’CCT TGA ATA ATA 
CCA CCA GTT G-3’ 
5’nucleotide at 
position 2467) 
 
 
(5′ nucleotide at 
position 3040) 
 
grlB 
 
Forward 
primer 
 
Reverse 
primer 
5’-TGT TGT GTC TGT 
TCG TAT TCC-3’ 
 
5’-GCA CCA TCA GTA 
TCA GCA TC-3’ 
(5′ nucleotide at 
position 1353)  
(5′ nucleotide at 
position 1910) 
 
gyrA 
Forward 
primer 
 
Reverse 
primer 
5’-GAG TGT TAT CGT 
TGC TCG TG-3’ 
 
5’-GAC GGC TCT CTT 
TCA TTA CC-3’ 
(5′ nucleotide at 
position 2333)  
 
(5′ nucleotide at 
position 2725) 
gyrB 
Forward 
primer 
 
Reverse 
primer 
5’-CCA CAA GTC GCA 
CGT ACA G-3’ 
 
5’-ATC CAC ATC GGC 
ATC AGT C-3’ 
(5′ nucleotide at 
position 1407)  
 
(5′ nucleotide at 
position 1817). 
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The temperature setup was done for the following steps 
Holding time 95° C for 5 minutes 
Denaturation 95°C for 30 seconds 
Annealing 46°C for 45 seconds 
Elongation 72° C for 59 minutes 
Final elongation 72°C for 7 minutes 
At the end of 30 cycles the amplified products were obtained. 
GEL ELECTROPHORESIS 
1. Sterile beaker was taken, 1x buffer was prepared, and 80 ml of 1x 
buffer was added with 0.76 grams of agarose powder and then kept in 
the micro wave oven for melting for 3 minutes. 
2. After 3 minutes the agarose was cooled to 40°c, to this 2 micro litre 
of Ethidium bromide was added. 
3. In 80 ml trough the agarose gel was poured with 15 numbered comb 
to make wells. After the agar gets solidified the comb was taken out. 
4. In the first well the 100 base pair ladder was added to the rest of the 
wells the amplified DNAs were added. 
5. The gel was run at 95 volts for 45 minutes and the appearance of 
bands were noted under UV light. 
6. The bands at 550 base pairs indicates grlA gene. 
7. The bands at 463 base pairs indicates grlB gene. 
8. The bands at 373 base pairs indicates gyrA gene. 
9. The bands at 392 base pairs indicates gyrB gene.  
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RESULTS 
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A total of 24,024 samples of pus, blood, wound swab, tracheal aspirate 
and urine were processed in microbiology laboratory between  April 2016 to 
July 2017. The incidence of Staphylococcus aureus from the samples were 
3.5%.  
Figure: 1 shows the distribution of Staphylococcus aureus that were resistance 
to fluroquinolones was about 120 among the total 859 isolates received from 
various samples. It was found to be 14.3% 
 
Figure: 2 depicts the distribution of Staphylococcus aureus from various 
clinical samples received  which was most commonly isolated from  pus 
sample 72%,followed by14% from blood 8% from tracheal aspirate and 6% 
from urine sample  
Illustration 1: Gram’s stain picture shows the gram positive cocci in clusters.  
 
Illustration 2. Growth of Staphylococcus aureus as beta haemolytic golden 
yellow colonies on blood agar.  
Growth on Mac Conkey agar showing small lactose fermenting colonies in 
Illustration 3. 
Bio chemical tests to differentiate Staphylococcus aureus. e.g. Tube coagulase, 
Mannitol with both positive and negative controls  are shown in Illustrations 4 
& 5. 
Antibiotic sensitivity was performed by Disc diffusion and Agar dilution 
methods  Illustration 6 & 7. 
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Table 1 depicts the pattern of susceptibility for the isolates of Staphylococcus 
aureus for various antibiotics.  
 
Figure : 3 shows the pattern of fluroquinolones resistance  among the isolates 
of Staphylococcus aureus. 
 
Table 2 depicts the MIC for the fluroquinolones resistant Staphylococcus 
aureus.  
The molecular characterisation for the gyrA gyrB grlA grlB was done 
by Real time PCR and amplification by gel electrophoresis is shown in 
Illustrations 8, 9 & 10. 
 
The expression of grlB and gyrB was found in 24% of isolates which is 
depicted in Illustration 11. 
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Figure : 1 Distribution of fluroquinolones resistance among total number 
of  Staphylococcus aureus 
 
Figure : 2 Distribution of Staphylococcus aureus from various clinical 
samples. 
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14%
Staphylococcus aureus 
Fluroquinolone resistant
72%
6%
8% 14%
Blood 
Urine
Pus 
Tracheal
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Illustration 1: Gram’s stain shows 
the gram positive cocci in clusters.  
Illustration 2: Beta haemolytic golden 
yellow colonies on blood agar.  
Illustration 3: Small lactose 
fermentors on MacConkey agar 
Illustration 4: Tube coagulase and 
mannitol fermentation 
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Illustration 6: Antibiotic sensitivity by Disc diffusion 
 
 
Illustration 7: Agar dilution method 
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Table 1. Pattern of susceptibility of  the isolates of Staphylococcus aureus for 
various antibiotics. 
n= 120 
 
Antibiotic (µg ) Sensitive ( %) Resistance ( %) 
Vancomycin ( 30 µg ) 100 0 
Linezolid ( 30 µg) 100 0 
Amoxy-clav ( 30 µg ) 74 26 
Clinadamycin ( 2 µg ) 88 12 
Erythromycin ( 15 µg ) 69 31 
Penicillin ( 6 µg ) 13 87 
Ciprofloxacin ( 5 µg ) 0 100 
Levofloxacin (5 µg ) 0 100 
Ofloxacin ( 5 µg) 0 100 
Cefoxitin( 10 µg) 37 73 
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Table 2 : Minimum Inhibitory Concentration (MIC) for the Fluroquinolone 
resistant Staphylococcus aureus. 
 
Antibiotic MIC 8 - 16µg MIC 16 - 32 µg MIC  32 - 64 µg 
Ciprofloxacin 52 38 30 
Levofloxacin 16 45 39 
Ofloxacin 18 43 49 
 
 
Figure 3 : Pattern of Fluroquinolone resistance in MSSA & MRSA. 
n= 120 
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Illustration 8: DNA Amplification (Thermocycler) 
 
 
 
Illustration 9: Gel electrophoresis 
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Figure : 4 Shows Distribution of Flouroquinolone resistant genes among 
test isolates 
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Illustration 10: The molecular characterisation for the gyrA gyrB grlA grlB 
done by Real time PCR. 
 
 
          
 
                     
 
                  
 
 
 
 
 
 
 
 
 
 
grlA gene 
gyrA gene 
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Illustration 11: Expression of grlB and gyrB genes among isolates of 
Staphylococcus aureus 
 
 
 
 
 
 
grlB gene 
gyrB gene 
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DISCUSSION  
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Staphylococcus aureus constitutes an important pathogen and is found 
to be colonised in approximately 30% of the population who are asymptomatic. 
Drug resistance has evolved due to increasing inadvertent use of high end 
antibiotics and the incidence of multidrug resistant bacteria is emerging 
rapidly. 
 The incidence of MRSA in our study was found to be 74%. This 
correlates well with other studies in and around world. MRSA isolates reported 
across various parts of the world range between 28 % to 87%.68 
Literature surveys reveal that the high percentages of isolates are of 
MRSA are found to be resistant to fluroquinolones as compared to MSSA. In 
our study 74% of MRSA were resistant to fluroquinolones among which most 
predominant was 43.3% to ciprofloxacin (43.3%) followed by ofloxacin 
(37.5%) and levofloxacin (34.2%). 
 MRSA colonisation and infection in patients relates to the effect of 
fluroquinolones and cotrimoxazole. Among the isolates of MRSA tested , in 
one study from patients 74% resistant to ciprofloxacin and 68% were resistant 
to cotrimoxazole were noted. In our study ,among clinical isolates of MSSA, 
26% were resistant to ciprofloxacin and 32% were resistant to cotrimoxazole. 
High prevalence of MRSA (64%) was observed from pyogenic 
infections followed by blood stream infections. In a study in New Delhi high 
prevalence of MRSA 35% in ward and 43% in ICU was observed from blood 
culture specimens69.  
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 Anti microbial susceptibility testing of isolates of Staphylococcus 
aureus showed maximum sensitivity to vancomycin (100%) , linezolid (100 
%)followed by clindamycin( 88% ) amoxyclav( 74% )..Highest resistance was 
noted for ciprofloxacin followed by ofloxacin.  
 First generation cephalosporins form the main stay of treatment for 
MSSA infections in patients intolerant to anti staphylococcal penicillins. If the 
patient has been empirically started on vancomycin and the culture report 
reveals MSSA de-escalation to beta lactams is the preferred mode of treatment. 
Glycopeptides- vancomycin and teicoplanin should be used only as a last resort 
and reserve drug.70 
 The minimum inhibitory concentration susceptibility profile to 
fluroquinolones was tested by agar dilution method. Among the 120 isolates of 
Staphylococcus aureus tested MIC value 32 to 64µg for ciprofloxacin, 16 to 
32µg for Ofloxacin and 8 to 16µg for Levofloxacin. The range of MIC value 
for fluroquinolones was between 32 to 64µg for MRSA as against 8 to 16µg for 
MSSA.  
 Studies on ocular infections have reported ciprofloxacin resistance 
ranging from 3 to 11% as compared to Levofloxacin 25.5%. Increasing 
resistance among Staphylococcus aureus isolates (MSSA) for ciprofloxacin and 
levofloxacin poses a threat for management of infections as treatment choices 
are narrowed.71 
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 In another study fluoroquinolones resistant rate of 41.8% was found 
among Staphylococcus aureus isolates which was comparatively higher than 
similar reports which showed resistance range between 13% and 20.7%72, 73  
      The mechanism of genotypic resistance to fluroquinolones in 
Staphylococcus aureus has been extensively studied. In majority of isolates 
single mutations in DNA topoisomerase IV and DNA gyrase have been 
reported. DNA topoisomerase IV is the primary target of fluroquinolones in 
Staphylococcus aureus with the first step to these agents being mutations in 
grlA.74 
   In our study a representative population of fifty isolates of resistant 
Staphylococcus aureus by both disk diffusion and agar dilution were subjected 
to real time PCR assay for detection of topoisomerase iv and gyrase. The 
results of our study showed majority of the isolates (72%) of Staphylococcus 
aureus were detected to express grlA and gyrA. This correlates well with other 
studies which report similar results.75 
           There have been reports showing one or two point mutations in the 
QRDR regions of both grlA and gyrA genes to be the main mechanism of 
ciprofloxacin resistance among isolates of Staphylococcus aureus.75 as shown 
by pulsefieldgel electrophoresis studies. 
          We noted high level ciprofloxacin resistance for 43.3% of the isolates 
tested (MIC 32-64 µg  /ml) This level of high resistance is usually associated 
with grlA and gyrA mutations. This finding also correlates well with other 
studies.74 
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           Though other molecular methods for detection of fluroquinolones exist 
eg: Restricted fragment length polymorphism (RFLP), High performance liquid 
chromatography (HPLC) and gene sequencing, they are cumbersome and 
labour intensive. The advantages of Real time PCR include high sensitivity and 
the turnaround time is far less compared to other methods. In laboratories 
which have facilities for molecular testing of Real time PCR could be used as a 
routine diagnostic tool. 
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CONCLUSION 
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  Injudicious use of antibiotics has led to widespread emergence of 
resistant organisms. Newer compounds have been introduced in the market but 
inadvertent use of these drugs  by clinicians have left us with resistant bugs 
which are very difficult to eradicate. The strict implementation of antibiotic 
policy tailor made to the individual hospital needs and prompt regular audits of 
compliance to the same are the only means of saving the populations from 
newer pathogens and multi drug resistant bugs.  
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SUMMARY 
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• Among the isolates of Staphylococcus aureus the incidence of 
MRSA was found to be 74%. 
 
• The resistance to fluroquinolones among the total isolates of 
Staphylococcus aureus was 14%. 
 
• High level of ciprofloxacin resistance was noted among majority of 
the isolates tested (MIC: 32 to 64 µg  ml). 
 
• MIC to levofloxacin and ofloxacin ranged between (8 to 16 µg and 
16 to 32 µg ) respectively. 
  
• Real time PCR for detection of fluoroquinolone resistance showed 
grl A and gyr A to e the most predominant genes expressed. (72%). 
 
• A small proportion (24%)  expressed grl B and gyr B 
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ANNEXURE - II 
 
PREPARATION OF REAGENTS 
 
BLOOD AGAR: 
 
Sterile defibrinated sheep blood    7ml 
Nutrient agar (melted)                  100ml 
 
About 7ml of melted nutrient agar ,was poured as a base ,into sterile Petri 
dishes and allowed for  setting. This forms a thin base for pouring in the blood 
agar.Sterile defibrinated sheep blood (5-7%) was added to nutrient agar, the 
latter should be cooled to about 45-500c before blood is added.It was mixed 
well and  about 15ml of blood agar was poured over the base in each Petri dish. 
 
 
MAcCONKEY AGAR: 
 
Peptone            -    2.0gm 
Sodium chloride – 0.5gm 
Bile salt              -  0.5gm 
Lactose              -  1.0gm 
Agar                  -   1.5gm 
Distilled water   -  100ml 
 
 The ingredients except lactose were dissolved in distilled water by heating. pH 
was adjusted to 7.6 .1ml of 1% neutral red solution was added  to every 100ml 
of medium with lactose. Sterilized by autoclaving at 1210c for 15 minutes. 
  
MUELLER-HINTON AGAR 
 
Beef extract                 -    2.0gm 
Acidicase peptone      -    7.5gm 
Starch                         -  1.5gm 
Agar                           -  17.0gm 
Distilled water           - 1000ml 
 
The ingredients were dissolved in one litre of distilled water and mixed 
thoroughly. Heat with frequent agitation and boil for one minute. pH was 
adjusted  to 7.4 +/-0.2.Sterilized by autoclaving 
 
MANNITOL FERMENTATION MEDIUM: 
 
SUGAR SOLUTION: 
Sugar (Mannitol)                                           -  0.5gm 
Nutrient broth base                                         – 100ml 
Bromothymol blue indicator(0.2% alcoholic)- 1.2ml 
 
Sugar solution was prepared as described above. It was dispensed in 2-4ml 
quantities into test tubes (12x100mm) Autoclaving was done at 1150c for 10 
minutes. 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexure III – Plagiarism Check 
  
  
 
 
 
 
